Restore Mind Medicine

Conclusion 25,000 20,000 15,000 10,000 5,000 0 Executive & Director Compensation 2023 HI G&A R&D Overhead Core R&D December Source: Company SEC Filings. See [6] FCM Proposed MindMed FY2022 Phase III Started Cash: $94M Other R&D February 2026 MindMed Spending * $66M Phase III Complete Cash: $15M June 2026 FCM Proposed Budget ✓ $39M Submit NDA ✓ $27.8M Savings ✓ Core R&D 60% Increase December 2026 FDA Approval 15

View entire presentation